Donanemab: The Breakthrough Drug Ushering a New Era in Alzheimer’s Treatment

The FDA is anticipated to approve a third Alzheimer’s drug, donanemab, signaling progress in slowing the disease. The drug showed a 35% slowdown in cognitive…